Weekly Buzz: So far, Santa is Letting us Down

Kevin TraversDec 27 16:59 ET

Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock

Kevin TraversDec 27 10:52 ET

10 Industrials Stocks With Whale Alerts In Today's Session

BenzingaDec 26 12:35 ET

JPMorgan Says These 2 Value Stocks Are Among Its 'Best Idea' Picks for 2025

Yahoo FinanceDec 25 03:22 ET

Everbright: Maintains the "Buy" rating for ASCLETIS-B. ASC47 combined with semaglutide shows superior effects.

Everbright released a research report stating that ASCLETIS-B (01672) is actively laying out its strategies in the MASH and weight loss sectors, and its progress is among the best in the country. Considering the company's effective control over various expenses, the net income forecast for 2024-2025 has been adjusted to -0.261/-0.313 billion yuan (previously -0.284/-0.34 billion yuan), and a new net income forecast for 2026 is -0.322 billion yuan, maintaining a "Buy" rating. The company released experimental data on the weight loss and muscle gain treatment drug ASC47 combined with semaglutide in obese mice; this drug is a fat-targeting, once-a-month subcutaneous injection of a thyroid hormone receptor β agonist.

Sina Hong Kong StocksDec 24 03:33 ET

Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025

BarronsDec 24 01:30 ET